Revolutionary Liposomal Alpha-Lipoic Acid Formulation Breakthrough Announced
Discover advanced liposomal Alpha-Lipoic Acid formulation technology with 83% encapsulation efficiency and a 227.3 nm mean particle size, supporting scientific evaluation for pharmaceutical and nutraceutical formulation development.
KOLKATA, India: West Bengal Chemical Industries Ltd. (WBCIL) has published research evaluating a liposomal Alpha-Lipoic Acid (ALA) formulation developed using its LipoEdge™ liposomal technology. The study examines formulation characteristics relevant to ingredient developers, R&D teams, and pharmaceutical and nutraceutical manufacturers, including encapsulation efficiency, particle size distribution, morphology, and thermal behaviour.
ALA is an antioxidant involved in cellular redox processes and can help regenerate antioxidants such as vitamins C and E. Its physicochemical properties can present challenges during formulation development. Liposomal systems use phospholipid bilayers to incorporate active ingredients and provide a carrier system whose composition and particle characteristics can be assessed during development.
LipoEdge™ focuses on phospholipid quality, including purified phosphatidylcholine, and the physicochemical characterisation of resulting liposomes. In the ALA study, WBCIL used High-Performance Liquid Chromatography (HPLC), Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), Fourier Transform Infrared (FTIR) spectroscopy, and Differential Scanning Calorimetry (DSC) to evaluate the formulation.
Key Study Findings:
Encapsulation efficiency: HPLC analysis reported an encapsulation efficiency of 83% ± 3%, indicating that a substantial proportion of the ALA was entrapped within the liposomal vesicles under the study conditions.
Particle characteristics: DLS analysis measured a mean particle size of 227.3 nm for liposomal ALA, compared with 370.3 nm for non-liposomal ALA. The polydispersity index (PDI) was 0.3329 for the liposomal formulation and 0.4699 for the non-liposomal sample, indicating less particle-size variation in the liposomal sample. The measured zeta potential was −30.79 mV, compared with −26.35 mV for non-liposomal ALA.
Structural and thermal characterisation: SEM images showed rounded morphology in the liposomal sample compared with the irregular structures observed in non-liposomal ALA. FTIR and DSC results provided additional information on the functional-group environment and thermal behaviour of the formulated material.
What This Means
The study shows how WBCIL applied LipoEdge™ technology to develop and characterise a liposomal Alpha-Lipoic Acid formulation. Its encapsulation and particle data give formulation teams a basis for evaluating the ingredient and planning development. Clinical studies, however, are necessary to determine whether these findings indicate better bioavailability or health outcomes.
To Summarise
LipoEdge™ liposomal ALA focuses on better encapsulation, particle characteristics, and thermal behaviour. The results support evaluation for pharmaceutical and nutraceutical applications. The findings set a new benchmark for nanotechnology and aim to improve health.
Product information: https://www.thelipoedge.com/product/liposomal-pharmaceuticals/liposomal-alpha-lipoic-acid/
Technical and commercial enquiries: https://www.thelipoedge.com/contact/
References
Gupta Banerjee, P., Paul, A., Chakraborty, A., & Kundu, S. (2025). Enhancing the stability and bioavailability of alpha-lipoic acid: Development and evaluation of a liposomal formulation by West Bengal Chemical Industries Ltd. International Journal of Pharmaceutical Sciences and Drug Analysis, 5(1), 39-48.
ALA is an antioxidant involved in cellular redox processes and can help regenerate antioxidants such as vitamins C and E. Its physicochemical properties can present challenges during formulation development. Liposomal systems use phospholipid bilayers to incorporate active ingredients and provide a carrier system whose composition and particle characteristics can be assessed during development.
LipoEdge™ focuses on phospholipid quality, including purified phosphatidylcholine, and the physicochemical characterisation of resulting liposomes. In the ALA study, WBCIL used High-Performance Liquid Chromatography (HPLC), Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), Fourier Transform Infrared (FTIR) spectroscopy, and Differential Scanning Calorimetry (DSC) to evaluate the formulation.
Key Study Findings:
Encapsulation efficiency: HPLC analysis reported an encapsulation efficiency of 83% ± 3%, indicating that a substantial proportion of the ALA was entrapped within the liposomal vesicles under the study conditions.
Particle characteristics: DLS analysis measured a mean particle size of 227.3 nm for liposomal ALA, compared with 370.3 nm for non-liposomal ALA. The polydispersity index (PDI) was 0.3329 for the liposomal formulation and 0.4699 for the non-liposomal sample, indicating less particle-size variation in the liposomal sample. The measured zeta potential was −30.79 mV, compared with −26.35 mV for non-liposomal ALA.
Structural and thermal characterisation: SEM images showed rounded morphology in the liposomal sample compared with the irregular structures observed in non-liposomal ALA. FTIR and DSC results provided additional information on the functional-group environment and thermal behaviour of the formulated material.
What This Means
The study shows how WBCIL applied LipoEdge™ technology to develop and characterise a liposomal Alpha-Lipoic Acid formulation. Its encapsulation and particle data give formulation teams a basis for evaluating the ingredient and planning development. Clinical studies, however, are necessary to determine whether these findings indicate better bioavailability or health outcomes.
To Summarise
LipoEdge™ liposomal ALA focuses on better encapsulation, particle characteristics, and thermal behaviour. The results support evaluation for pharmaceutical and nutraceutical applications. The findings set a new benchmark for nanotechnology and aim to improve health.
Product information: https://www.thelipoedge.com/product/liposomal-pharmaceuticals/liposomal-alpha-lipoic-acid/
Technical and commercial enquiries: https://www.thelipoedge.com/contact/
References
Gupta Banerjee, P., Paul, A., Chakraborty, A., & Kundu, S. (2025). Enhancing the stability and bioavailability of alpha-lipoic acid: Development and evaluation of a liposomal formulation by West Bengal Chemical Industries Ltd. International Journal of Pharmaceutical Sciences and Drug Analysis, 5(1), 39-48.
- Contact Email
- [email protected]
- Issued By
- LipoEdge
- Phone
- 06290900900
- Business Address
- AG-112, Room No. 604, 6th Floor, Sector-II, Baishaki, Bidhannagar, Salt Lake, West Bengal
- Country
- India
- Categories
- Health · Manufacturing · Pharma
- Last Updated
- October 26, 2026